Business
INmune Bio, Inc. Announces Company’s CSO Dr. Mark Lowdell to Co-Host the “NK Cells in Solid Tumors” Workshop at Innate Killer Summit
The Company also Plans on Sharing INKmune™ Patient Case Studies Boca Raton, Florida, March 30, 2022 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB)
About this update from Inmune Bio Inc.
[{"type":"text","content":"The Company also Plans on Sharing INKmune™ Patient Case Studies\nBoca Raton, Florida, March 30, 2022 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (“INMB” or “the Company”), a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, is pleased to announce the Company’s Chief Scientific Officer Dr. Lowdell will be leading a workshop on the role of natural killer (NK) cells in the treatment of solid tumors. The presentation, titled, “Challenges of NK Immunotherapy of Solid Tumors: Potentiation of intra-tumoral NK Function,” is part of the 7th Innate Killer Summit being held in San Diego from March 30 to April 1. The Innate Killer Summit conference is widely viewed as one of the most important meetings in translational NK cell immunotherapy. “NK cells are established as an important part of the anti-tumor immune response, but their clinical application has been difficult, especially in solid tumors,” said Dr. Lowdell, CSO of INmune Bio. “This workshop strives to understand why NK cell therapies fail in solid tumors and how we can improve the therapeutic response and practicality of NK therapeutics. Our aim is to make NK cells effective in the fight against cancer so patients will benefit.” Prof. Lowdell has identified several of the problems to be discussed, and addressed: What is the best way to deliver a cancer killing NK cell? The different strategies to deliver NK cell therapies include a complex mix of genetic engineering, cytokine use, ex-vivo processing and manufacturing. Complexity is a barrier to use. How do we improve the delivery of effective NK cell therapy to patients? Persistence of NK cell killing is important for success – Short survival of NK therapeutics hampers efficacy. Are there ways to improve therapeutic persistence of tumor killing NK cells?Why is the therapeutic response to NK therapies suboptimal in solid tumors? The hostile biology of the tumor micro-environment (TME) in solid tumors affects the activity of NK cells in many ways. Identifying and overcoming barriers to NK function in the TME will improve the chance of success.Logistics and delivery: NK cell therapies must balance therapeutic value with practicality and access. The manufacture, storage, and delivery of NK cell therapeutics can be complex. Strategies to simplif...